Professur für Innere Medizin (Nephrologie)


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial (2021) Mahfoud F, Bloch MJ, Azizi M, Wang Y, Schmieder R, Lobo MD, Sharp ASP, et al. Journal article Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes (2021) Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Dahlmann A, Kopp C, et al. Journal article Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure (2021) Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, et al. Journal article Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (2021) Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, et al. Journal article Chronic Kidney Disease - Diagnosis and Treatment (2021) Galle J, Schmieder R, Weinreich T Journal article Application of win ratio methodology in the Global SYMPLICITY Registry for patients with atrial fibrillation or obstructive sleep apnea (2021) Mahfoud F, Mancia G, Ukena C, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, et al. Conference contribution Reasons for antihypertensive medication nonadherence influence physician preferences for hypertension management (2021) Schmieder R, Kandzari DE, Wang TD, Lee YH, Haro C, Pathak A Conference contribution Predictors of blood pressure response after renal denervation beyond pretreatment blood pressure (2021) Schmieder R, Delles C, Lauder L, Ott C, Boehm M, Mahfoud F Conference contribution Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin (2021) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Conference contribution Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure (2021) Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, et al. Journal article